Shareholders are rewarding the kinds of companies they punished a year ago.
And an expanded market awaits its colorectal cancer blood test, though Exact will benefit first.
The quest for the Grail is beset with challenges.
A lot of money is sloshing around, and medical device start-ups are reaping the benefits.
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.